HC Wainwright Issues Pessimistic Estimate for DMAC Earnings

Key Points

• HC Wainwright cut its FY2029 EPS estimate for DiaMedica to $0.14 (from $0.15) and projects FY2030 EPS of $0.56, while the consensus for the current full year remains a loss of ($0.59) per share.
• DiaMedica reported Q1 EPS of ($0.17), matching estimates, but revenue was essentially zero at ($0.03) million versus analyst expectations of $13.5 million.
• The stock trades around $6.42 with a market cap of $334.3M, and analysts hold a consensus of Moderate Buy (five Buys, one Sell) with an average price target of $12.33.

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Free Report) - Research analysts at HC Wainwright reduced their FY2029 EPS estimates for DiaMedica Therapeutics in a research note issued to investors on Wednesday, April 1st. HC Wainwright analyst M. Caufield now expects that the company will post earnings of $0.14 per share for the year, down from their prior estimate of $0.15. The consensus estimate for DiaMedica Therapeutics' current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for DiaMedica Therapeutics' FY2030 earnings at $0.56 EPS.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last posted its earnings results on Monday, March 30th. The company reported ($0.17) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.17). The firm had revenue of ($0.03) million during the quarter, compared to analyst estimates of $13.50 million.

DMAC has been the topic of a number of other reports. Lake Street Capital reiterated a "buy" rating on shares of DiaMedica Therapeutics in a research note on Monday, January 5th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of DiaMedica Therapeutics in a report on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $12.33.

DiaMedica Therapeutics Price Performance

DMAC stock opened at $6.42 on Thursday. DiaMedica Therapeutics has a 52-week low of $3.19 and a 52-week high of $10.42. The company has a 50-day moving average of $7.84 and a two-hundred day moving average of $7.64. The stock has a market capitalization of $334.33 million, a price-to-earnings ratio of -9.17 and a beta of 1.09.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Strs Ohio lifted its stake in shares of DiaMedica Therapeutics by 19.7% in the third quarter. Strs Ohio now owns 9,100 shares of the company's stock valued at $63,000 after buying an additional 1,500 shares during the period. World Investment Advisors increased its stake in DiaMedica Therapeutics by 7.3% during the third quarter. World Investment Advisors now owns 34,325 shares of the company's stock valued at $236,000 after acquiring an additional 2,350 shares during the period. Rhumbline Advisers raised its holdings in DiaMedica Therapeutics by 14.5% in the 3rd quarter. Rhumbline Advisers now owns 27,357 shares of the company's stock valued at $188,000 after acquiring an additional 3,463 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in DiaMedica Therapeutics in the 4th quarter valued at approximately $29,000. Finally, BNP Paribas Financial Markets lifted its position in shares of DiaMedica Therapeutics by 24.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 18,882 shares of the company's stock worth $74,000 after acquiring an additional 3,709 shares during the period. Institutional investors and hedge funds own 10.12% of the company's stock.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc NASDAQ: DMAC is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company's lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica's research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.